-transparent.png){kind=logo}
Twenty patients with osteosarcoma were treated with exogenous human leukocyte interferon for periods ranging from 6 to 18 months. Eleven of them remained free from detectable tumour growth during this treatment. Blood samples from all patients were tested for antibodies against interferon and against impurities in the interferon preparations. No patient developed detectable levels of neutralizing antibodies against interferon. All patients formed antibodies against contaminants in the concentrated crude interferon and the partially purified interferon preparation which had been used for treatment.
Related Publications
S Ingimarsson, and
K Cantell, and
G Carlström, and
B Dalton, and
K Paucker, and
H Strander
November 1986,
The Journal of clinical endocrinology and metabolism,
S Ingimarsson, and
K Cantell, and
G Carlström, and
B Dalton, and
K Paucker, and
H Strander
November 1986,
Cancer treatment reports,
S Ingimarsson, and
K Cantell, and
G Carlström, and
B Dalton, and
K Paucker, and
H Strander
June 1977,
The New England journal of medicine,
S Ingimarsson, and
K Cantell, and
G Carlström, and
B Dalton, and
K Paucker, and
H Strander
January 1988,
Seminars in surgical oncology,
S Ingimarsson, and
K Cantell, and
G Carlström, and
B Dalton, and
K Paucker, and
H Strander
January 1988,
Acta gastroenterologica Latinoamericana,
S Ingimarsson, and
K Cantell, and
G Carlström, and
B Dalton, and
K Paucker, and
H Strander
March 1983,
American journal of ophthalmology,
S Ingimarsson, and
K Cantell, and
G Carlström, and
B Dalton, and
K Paucker, and
H Strander
May 1995,
Fertility and sterility,
S Ingimarsson, and
K Cantell, and
G Carlström, and
B Dalton, and
K Paucker, and
H Strander
January 1992,
Anticancer research,
S Ingimarsson, and
K Cantell, and
G Carlström, and
B Dalton, and
K Paucker, and
H Strander
April 1982,
American journal of clinical oncology,
S Ingimarsson, and
K Cantell, and
G Carlström, and
B Dalton, and
K Paucker, and
H Strander
August 1984,
JAMA,
